Last €22.38 EUR
Change Today +0.112 / 0.50%
Volume 30.9K
AFX On Other Exchanges
As of 3:35 PM 11/24/14 All times are local (Market data is delayed by at least 15 minutes).

carl zeiss meditec ag - br (AFX) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/9/13 - €25.04
52 Week Low
03/14/14 - €19.47
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CARL ZEISS MEDITEC AG - BR (AFX)

Related News

No related news articles were found.

carl zeiss meditec ag - br (AFX) Related Businessweek News

View More BusinessWeek News

carl zeiss meditec ag - br (AFX) Details

Carl Zeiss Meditec AG operates as a medical technology company worldwide. It operates through Ophthalmic Systems, Surgical Ophthalmology, and Microsurgery segments. The company provides various products and services in the fields of ophthalmology and optometry; neurosurgery; ear, nose, and throat; spine; plastic and reconstructive (P&R); dentistry; gynecology; and oncology. The company’s ophthalmic equipment and systems handle the diagnosis, progress monitoring, treatment, and follow-up treatment of ophthalmic syndromes comprising vision defects (refraction), cataract, glaucoma, and retinal disorders. It also provides ophthalmic implants consisting of intraocular lenses; and disposables. In addition, the company offers visualization products, such as surgical microscopes and loupes for neuro, spine, P&R, and dental surgeries, as well as for ear, nose, and throat surgeries; intraoperative radiation therapy devices to treat various tumors; and colposcopes for gynecological applications. Carl Zeiss Meditec AG serves physicians in various fields and hospitals through a distribution network of 40 sales companies and 100 agencies. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.

2,947 Employees
Last Reported Date: 08/15/14
Founded in 2002

carl zeiss meditec ag - br (AFX) Top Compensated Officers

Chairman of Management Board, Chief Executive...
Total Annual Compensation: €470.8K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €379.9K
Chief Sales Officer and Member of Management ...
Total Annual Compensation: €393.5K
Compensation as of Fiscal Year 2013.

carl zeiss meditec ag - br (AFX) Key Developments

Carl Zeiss Meditec AG Presents at HSBC Healthcare Day 2014, Nov-12-2014

Carl Zeiss Meditec AG Presents at HSBC Healthcare Day 2014, Nov-12-2014 . Venue: Hilton, Frankfurt, Germany.

Carl Zeiss Meditec AG Reports Revenue Results for the Fiscal Year 2014; Provides Earnings Guidance for the Full Fiscal Year of 2014

Carl Zeiss Meditec AG reported revenue results for the fiscal year 2014. For the period, the company has achieved preliminary revenue near the low end of forecast range of EBIT and EPS expected below the high previous year's level. The company has achieved revenue of approximately EUR 910 million at the low end of its forecast range of EUR 910 million to 940 million, based on preliminary data. The company provided earnings guidance for the full fiscal year of 2014. Earnings before interest and taxes (EBIT) as well as earnings per share (EPS) are expected below the high previous year's level.

Carl Zeiss Meditec AG Unveils New Optical Imaging Device

Carl Zeiss Meditec AG has unveiled the IOLMaster 700 with SWEPT Source Biometry, which identifies irregular geometries of the eye or insufficient fixation already during the diagnosis. Apart from optical biometry, it also offers OCT imaging across the entire length of the eye. The IOL Master 700 enables cataract surgeons to view the complete longitudinal section of the eye, from the cornea to the retina. Irregular eye geometries, for example tilting of the lens axis, are therefore easier to identify. It is expected that this will facilitate a reduction in refractive surprises. Imaging of the fovea in the macula lutea also allows physicians to check for correct fixation. Compared with previous procedures, in which the measurement result was derived from an A scan curve, the image-based measurement with the IOLMaster 700 brings both physician and patient added safety, as the expected refractive outcome can be more reliably predicted. As with the IOLMaster 500, this new device also simplifies the workflows prior to cataract surgery. The Reference Image option eliminates the need for manual pre-operative and intraoperative marking of the astigmatism axis on the patient's eye before implantation of a toric IOL, as well as the necessity of manual data transfer. Both were previously necessary for alignment of the toric lenses. The IOLMaster 700 is fully compatible with previous versions and provides access to the database of the User Group of Laser Interference Biometry. This database contains the lens constants of more than 270 IOL models and is based on more than 50,000 cataract operations. The unique telecentric keratometry allows particularly robust and reproducible measurement of the corneal surface.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AFX:GR €22.38 EUR +0.112

AFX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ellex Medical Lasers Ltd A$0.31 AUD 0.00
Iridex Corp $8.48 USD +0.05
LightPath Technologies Inc $1.19 USD -0.0184
Synergetics USA Inc $3.43 USD -0.10
Topcon Corp ¥2,602 JPY 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation AFX Industry Range
Price/Earnings 19.5x
Price/Sales 1.8x
Price/Book 2.4x
Price/Cash Flow 19.5x
TEV/Sales 1.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARL ZEISS MEDITEC AG - BR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at